EpiPen Prices, the Clinton Foundation, and Lead Exposure
Aug 31, 2016•56 min•Ep. 54
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Why did EpiPen's price skyrocket 400 percent over the past decade? Sarah and Matt dive into the complex world of American drug pricing to find out. Also on this episode: understanding why the Clinton Foundation gets so much scrutiny, and a white paper of the week that shows how problematic a small level of lead exposure can be.
Learn more about your ad choices. Visit podcastchoices.com/adchoices
For the best experience, listen in Metacast app for iOS or Android